tiprankstipranks
Advertisement
Advertisement

PCBIO1R Stock Latest News

BioSpectator Inc Highlights Optioned EGFR Degrader and Expanding Oncology Pipeline in Weekly Roundup
Private CompaniesBioSpectator Inc Highlights Optioned EGFR Degrader and Expanding Oncology Pipeline in Weekly Roundup
2d ago
BIO1R
AstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential
PremiumPrivate Companies
AstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential
4d ago
BIO1R
AstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential Over $500 Million
PremiumPrivate Companies
AstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential Over $500 Million
5d ago
BIO1R
Compass Therapeutics’ Tovecimig Trial Data Add PFS Strength But Raise OS Questions
PremiumPrivate Companies
Compass Therapeutics’ Tovecimig Trial Data Add PFS Strength But Raise OS Questions
6d ago
BIO1R
Compass Therapeutics Faces Mixed Survival Data for Tovecimig in Biliary Tract Cancer Trial
PremiumPrivate Companies
Compass Therapeutics Faces Mixed Survival Data for Tovecimig in Biliary Tract Cancer Trial
7d ago
BIO1R
Hanmi Explores Oral EP300 Degrader Strategy for Solid Tumors
PremiumPrivate CompaniesHanmi Explores Oral EP300 Degrader Strategy for Solid Tumors
7d ago
BIO1R
ReCerise Advances First-in-Class TM4SF5 Antibody Toward Clinical Stage
Premium
Private Companies
ReCerise Advances First-in-Class TM4SF5 Antibody Toward Clinical Stage
7d ago
BIO1R
Hanmi Explores Oral EP300 Degrader Strategy for Solid Tumors
Premium
Private Companies
Hanmi Explores Oral EP300 Degrader Strategy for Solid Tumors
7d ago
BIO1R
ReCerise Therapeutics Advances TM4SF5 Antibody Toward Early Clinical Development
PremiumPrivate Companies
ReCerise Therapeutics Advances TM4SF5 Antibody Toward Early Clinical Development
7d ago
BIO1R
BioSpectator Inc – Weekly Recap
PremiumPrivate Companies
BioSpectator Inc – Weekly Recap
9d ago
BIO1R
Y-Biologics Advances Cis-Acting Trispecific IL-2 Antibody Program Toward Planned IND Filings
PremiumPrivate Companies
Y-Biologics Advances Cis-Acting Trispecific IL-2 Antibody Program Toward Planned IND Filings
10d ago
BIO1R
Y-Biologics Advances Trispecific IL-2 Checkpoint Antibody Strategy Toward Planned IND Filings
PremiumPrivate Companies
Y-Biologics Advances Trispecific IL-2 Checkpoint Antibody Strategy Toward Planned IND Filings
10d ago
BIO1R
ABL Bio Advances B7-H3xROR1 Bispecific ADC ABL206 Into Early Clinical Development
PremiumPrivate CompaniesABL Bio Advances B7-H3xROR1 Bispecific ADC ABL206 Into Early Clinical Development
11d ago
BIO1R
ABL Bio Advances B7-H3xROR1 ADC ABL206 Into Early Clinical Stage
Premium
Private Companies
ABL Bio Advances B7-H3xROR1 ADC ABL206 Into Early Clinical Stage
12d ago
BIO1R
ReCerise Therapeutics Advances TM4SF5 Antibody Toward Clinical Development
Premium
Private Companies
ReCerise Therapeutics Advances TM4SF5 Antibody Toward Clinical Development
12d ago
BIO1R
ABL Bio Advances EGFR x MUC1 ADC ABL209 Toward Phase 1 With Differentiated Design
PremiumPrivate Companies
ABL Bio Advances EGFR x MUC1 ADC ABL209 Toward Phase 1 With Differentiated Design
12d ago
BIO1R
ReCerise Therapeutics Advances First‑in‑Class TM4SF5 Antibody Targeting Gastrointestinal Cancers
PremiumPrivate Companies
ReCerise Therapeutics Advances First‑in‑Class TM4SF5 Antibody Targeting Gastrointestinal Cancers
12d ago
BIO1R
ABL209 Bispecific ADC Strategy Highlighted Ahead of Phase 1 Initiation
PremiumPrivate Companies
ABL209 Bispecific ADC Strategy Highlighted Ahead of Phase 1 Initiation
12d ago
BIO1R
HLB Panagene Advances PNA-Based Antibody–Oligonucleotide Conjugate Program in DMD
PremiumPrivate Companies
HLB Panagene Advances PNA-Based Antibody–Oligonucleotide Conjugate Program in DMD
17d ago
BIO1R
HLB Panagene Advances PNA-Based Antibody-Oligonucleotide Conjugate Strategy for DMD
PremiumPrivate CompaniesHLB Panagene Advances PNA-Based Antibody-Oligonucleotide Conjugate Strategy for DMD
17d ago
BIO1R
NOBO Medicine Positions BTK Inhibitor Poseltinib for Rare Lymphoma Amid Immune Aging Focus
Premium
Private Companies
NOBO Medicine Positions BTK Inhibitor Poseltinib for Rare Lymphoma Amid Immune Aging Focus
28d ago
BIO1R
NOBO Medicine Refocuses Pipeline on Immune Aging and BTK Inhibitor Development
Premium
Private Companies
NOBO Medicine Refocuses Pipeline on Immune Aging and BTK Inhibitor Development
29d ago
BIO1R

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >